The arithmetic of biotech investing rarely gets starker than this: a company sitting on a potential blockbuster Lyme disease vaccine, yet bleeding cash at a rate that forces it to sell off real estate to stay afloat. Valneva’s first half of 2026 captures that contradiction in full — a net loss that ballooned to €63.3 million from €20.8 million a year earlier, even as the company notched a regulatory win in South America and pushed its most valuable pipeline asset closer to market.
The French vaccine maker’s locally produced chikungunya shot, developed with Brazil’s Instituto Butantan and marketed under the “Butantan-chik” brand, secured regulatory approval in Brazil in May. It is a meaningful feather in the cap for a company in the midst of a sweeping cost-reduction program — one that has involved headcount cuts, a reordering of R&D priorities, and streamlined global operations. The approval signals that the partnership pipeline retains momentum beyond the headline-grabbing Lyme collaboration with Pfizer.
That restructuring is now showing up on the income statement in painful fashion. The widened first-half loss stemmed from thinner gross margins on lower
The second quarter alone illustrates the strain: product sales dropped 21% to €33.5 million. For the annual guidance midpoint to be reached, the back half of the year will need to deliver a noticeable acceleration — a scenario management is clearly banking on.
A Property Sale That Speaks Volumes
Cash preservation has become the operative theme. Valneva has reached a preliminary agreement to sell its Nantes facility to local authority Nantes Métropole for €6.2 million, with closing expected in September. The sum is modest against a market capitalization of roughly €551 million, but the move underscores a company actively shedding assets while awaiting what it hopes will be a transformative regulatory decision.
Should investors sell immediately? Or is it worth buying Valneva?
That decision concerns the Lyme disease vaccine candidate developed with Pfizer. The European Medicines Agency accepted the marketing application for review just over a week ago, triggering an 8.0% jump in the share price. A ruling is expected within twelve months. Two additional clinical trials are also underway for the S4V2 vaccine candidate — a Phase 2 study assessing safety and immunogenicity in infants, plus a LimmaTech Biologics-sponsored Phase 2b human challenge trial — with data from both slated for the third quarter of 2026.
Analyst Caution Meets Market Enthusiasm
The equity story is playing out in two distinct timeframes, and the market’s mood has swung accordingly. First Berlin trimmed its price target on the stock to €4.40 from €4.50 on Tuesday, while maintaining a buy recommendation. The analysts cited weaker 2026 earnings expectations and higher net debt — a pointed reminder that the regulatory clock and the operational clock are not ticking in sync.
The share price tells a similar tale of competing forces. After the EMA validation, the stock climbed 8.0%, and over a 30-day horizon it has gained 34%. Yet the shares remain down 19% year-to-date and sit roughly 44% below their 52-week high of €5.34, reached in early October. The recent closing price of €3.00 stands nearly a quarter above the 50-day moving average — evidence that investors are rewarding recent headlines, even as the stock trades about 45% above its July low of €2.03.
The current price of €2.95 reflects a company that has shed a fifth of its value over the past year and remains nearly half below its peak. The gap between the 52-week high and the present level is a measure of how much skepticism has built up around Valneva’s ability to fund its ambitions.
What emerges is a portrait of a business in transition — one that has found a new market in Brazil, tightened its cost base, and secured regulatory traction for its most valuable asset, all while the financial statements tell a more sobering story. The S4V2 readouts in the third quarter will offer the next test of whether the pipeline can stand on its own merits beyond the Pfizer partnership. For now, the market seems to be asking whether the Lyme catalyst can carry the stock before the balance sheet runs out of patience.
Ad
Valneva Stock: Buy or Sell?! New Valneva Analysis from September 4 delivers the answer:
The latest Valneva figures speak for themselves: Urgent action needed for Valneva investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 4.
Valneva: Buy or sell? Read more here...
